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Abstract
Meconium ileus (MI), a life-threatening intestinal obstruction due to meconium with abnormal protein content, occurs in
approximately 15 percent of neonates with cystic fibrosis (CF). Analysis of twins with CF demonstrates that MI is a highly
heritable trait, indicating that genetic modifiers are largely responsible for this complication. Here, we performed regional
family-based association analysis of a locus that had previously been linked to MI and found that SNP haplotypes 59 to and
within the MSRA gene were associated with MI (P=1.99610
25 to 1.08610
26; Bonferroni P=0.057 to 3.1610
23). The
haplotype with the lowest P value showed association with MI in an independent sample of 1,335 unrelated CF patients
(OR=0.72, 95% CI [0.53–0.98], P=0.04). Intestinal obstruction at the time of weaning was decreased in CF mice with Msra
null alleles compared to those with wild-type Msra resulting in significant improvement in survival (P=1.2610
24). Similar
levels of goblet cell hyperplasia were observed in the ilea of the Cftr
2/2 and Cftr
2/2Msra
2/2 mice. Modulation of MSRA, an
antioxidant shown to preserve the activity of enzymes, may influence proteolysis in the developing intestine of the CF fetus,
thereby altering the incidence of obstruction in the newborn period. Identification of MSRA as a modifier of MI provides new
insight into the biologic mechanism of neonatal intestinal obstruction caused by loss of CFTR function.
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Introduction
Cystic fibrosis (CF; MIM 219700, http://www.omim.org) is an
autosomal recessive condition caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR; MIM
602421) gene [1]. The earliest manifestation of CF is meconium
ileus(MI),aprenatalobstructionofthesmallintestineat the ileocecal
junction. Meconium, the intestinal contents of the developing gut
that form the first bowel movement, has an abnormally high protein
content in CF neonates thought to be due to defective proteolysis
[2–4]. Impaction of the tenacious meconium results in intestinal
obstruction in approximately 15% of CF newborns. This compli-
cation presents as abdominal distention, failure to pass meconium,
and vomiting and was near universally fatal in CF newborns until
effective treatment (enema or surgery) was developed. The long term
effectsofMIhavebeen a matter ofdebate as someinvestigators have
reported worse outcomes while others observed no significant
differences from CF subjects without MI [5–7].
Genetic modifiers have been implicated in the development of
MI for over 40 years as recurrence risk for this complication in
siblings with CF (,0.25) has consistently been shown to be higher
than that in unrelated individuals with CF (,0.15) [8–12]. Con-
cordance analysis in monozygous and dizygous twins demonstrat-
ed that the heritability of MI approaches 1.0, confirming that
modifier genes play a substantial role in MI [12]. CFTR also
contributes to risk as MI almost exclusively manifests in CF
subjects with exocrine pancreatic insufficiency (PI), which is highly
correlated with CFTR genotype [13,14]. Furthermore, the
incidence of MI appears to vary among CFTR mutations that
confer PI. For example, the amino acid substitution p.Gly551Asp
(‘‘G551D’’) has been associated with reduced risk of MI compared
to the most common CFTR mutation that causes a deleterious in-
frame deletion of one amino acid (p.Phe508del, ‘‘delta F508’’)
[15,16].
Initial attempts to identify MI modifier genes in humans utilized
localization results from mouse studies. Mice with disruption of
Cftr present with an MI-like phenotype; however, it differs from
human MI in several respects. First, intestinal obstruction in CF
mice causes mortality shortly after birth and at the time of weaning
with the introduction of solid food [17–19]. Life-threatening
PLoS Genetics | www.plosgenetics.org 1 March 2012 | Volume 8 | Issue 3 | e1002580obstruction in humans occurs in the perinatal period, while
episodes of variable severity termed distal intestinal obstruction
syndrome (DIOS) can also occur throughout life (5 to 12 episodes
per 1,000 patient-years), especially in adults with PI and as a post-
operative complication of surgical intervention, particularly organ
transplantation [20,21]. Second, obstructive lesions in CF mice
have been observed in the jejunum, ileum and colon, compared to
predominantly ileo-colic localization in humans [22]. Third,
pancreatic exocrine disease is much less prominent in mouse
models of CF [17,23,24]. On the other hand, there are instructive
genetic similarities between mice and humans with CF. Cftr alleles
influence the rate and severity of murine intestinal obstruction
[17,25–28] and strain-specific differences in the penetrance of
intestinal obstruction indicate that different modifier genes
underlie obstruction at birth and at weaning [19]. Candidate
gene approaches in CF mice have revealed that decreased
expression of the sodium hydrogen exchanger 3 (Nhe3) or mucin
1( Muc1) or over-expression of the chloride calcium channel
activated 3 protein (Clca3/Gob5) can reduce intestinal obstruction
at weaning [29–31].
Newer animal models of CF have provided additional clues in
the search for modifiers of MI. CFTR knock-out ferrets and pigs
have been shown to develop intestinal obstruction that is
anatomically and temporally equivalent to that observed in
humans; however, the phenotype is highly penetrant in these
animals (75% and 100%, respectively) [32,33]. Animal models of
CF and heritability studies in humans suggest that intestinal
obstruction due to loss of CFTR function is a consistent feature,
and that the incomplete penetrance of this trait in humans with CF
is likely due to the presence of genetic modifiers. We present here
the results of a regional association analysis of a linked locus on
chromosome 8 [12], and report the identification and functional
confirmation of a modifier gene for MI in humans and mice
with CF.
Results
Regional association analysis of CF patients implicates
variants near and within MSRA as modifiers of MI
To investigate a region on chromosome 8 that had previously
shown linkage to MI [12], transmission analysis of SNPs was
performed using families from the Cystic Fibrosis Twin and
Sibling Study (TSS). As MI is associated with an increased
recurrence risk among siblings, we enriched for genes that modify
this phenotype by analyzing 133 families in which at least one
subject was affected with MI (26 MI concordant and 91 discordant
pairs, 2 concordant and 8 discordant sets of 3, and 6 singletons;
Table 1). Since MI rarely occurs in the absence of PI, individuals
were excluded if their CFTR genotypes were associated with
exocrine pancreatic sufficiency (PS) (n=7) or if they clinically
demonstrated PS (n=5). All SNPs on the Illumina 610-Quad
genotyping panel that passed rigorous quality control (2,896 SNPs)
[34] were included from an approximately 9 Mb region within the
linkage locus where the SNP LOD score exceeded 1.0 (bound-
aries: rs2945913-rs2285274; green shaded area in linkage plot
inset, Figure 1). Parental genotypes were utilized to test the
transmission of SNP alleles using pedigree-based association
testing (PBAT), an extension of the transmission disequilibrium
test that is robust against population stratification [35,36]. A
cluster of SNPs proximal to and within MSRA (MIM 601250)
showed evidence of association with MI when an additive mode of
inheritance was assumed (Figure 1). One SNP within this cluster 59
to MSRA, rs614197, exceeded the threshold for region-wide
significance (P=8.35610
26, Bonferroni corrected P=0.024).
However, this SNP was not associated with MI in a sample of
unrelated CF patients from the Canadian Consortium for Genetic
Studies (CGS; Table 1).
Lack of significant association between MI and rs614197 in the
CGS sample led us to question whether the initial observation in
the TSS families was spurious, or if detection of association could
be confounded by interacting loci [37] or by heterogeneity of effect
of alleles at the locus [38,39]. To test the latter concept, we used
haplotype analysis to search for additional genetic variation
associated with MI in the region surrounding MSRA. Haplotypes
derived from a sliding window of three consecutive SNPs across a
Author Summary
Cystic fibrosis (CF) is a monogenic disease with consider-
able phenotypic variability. About 15% of newborns with
CF suffer from an intestinal obstruction called meconium
ileus (MI), and studies in CF twins have shown that
modifier genes play a substantial role in the development
of this complication. We used a family-based study design
to enrich for genetic modifiers of MI and found that
variations in the MSRA gene, represented by combinations
of SNPs, or haplotypes, were protective against this
manifestation of CF. We investigated association between
one of the MSRA haplotypes and MI in an independent
sample of CF patients and showed that it had a similar
protective effect. Furthermore, CF mice lacking Msra
expression had lower mortality due to intestinal obstruc-
tion at the time of transitioning to solid food and lived
longer than CF mice with normal Msra, thus supporting
the protective effect of the haplotype we observed in
human CF subjects. The identification of modifiers of MI
such as MSRA offers new insight into the mechanism of
this life-threatening complication of CF.
Table 1. Patient characteristics.
CF Twin and Sibling Study (TSS) Canadian Consortium for Genetic Studies (CGS)
MI No MI (Families)
a No MI (Entire Sample)
b MI No MI
Subjects 166 104 766 220 1,163
Mean Age in Years 6 SD 16.366.8 16.766.7 18.969.5 23.168.7 26.3610.6
Females (%) 82 (49.4) 52 (50.0) 358 (46.7) 108 (49.1) 532 (45.7)
p.Phe508del Homozygotes (%) 104 (62.7) 61 (58.7) 402 (52.5) 152 (69.1) 699 (60.1)
aPrimary analysis included subjects from 133 ‘‘MI families’’ in which at least one sibling had MI.
bCFTR mutation-specific analysis (i.e. p.Gly551Asp vs. p.Phe508del) utilized the entire TSS sample.
doi:10.1371/journal.pgen.1002580.t001
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rs4240673) were tested for transmission distortion under an additive
geneticmodel (Figure S1). We used combinations of three SNPs as a
compromise between the number of haplotypes generated and the
penalty incurred by multiple testing. Two haplotypes exceeded the
threshold for significant regional association after Bonferroni
correction for 2,890 different haplotypes observed in the 133
families studied (Table 2). The combination of rs10903323 T,
rs4840475 G and rs17151637 A (T-G-A) spanning a 3.5 kb region
in intron 3 of MSRA (Figure 2) was significantly over-transmitted to
individuals without MI, or in other words had a protective effect on
MI (54 informative families, raw P=1.08610
26; Bonferroni
P=3.13610
23). In the entire TSS cohort, the T-G-A haplotype
frequency was 14.9% (13.0% in subjects with MI, 25.0% in those
without MI). A second, overlapping haplotype (Figure 2) containing
two of the same SNP alleles as the T-G-A haplotype (rs4840475 G,
rs17151637 A, plus rs6601427 C; Table 2) similarly demonstrated
association with the absence of MI (48 informative families, raw
P=1.17610
25; Bonferroni P=0.034). Another haplotype located
just 59 to MSRA showed nearly significant over-transmission to
individuals with MI, indicating that it conferred risk for MI (59
informative families, raw P=1.99610
25; Bonferroni P=0.057).
Interestingly, this haplotype included rs614197, the SNP that was
associated with MI in the initial single marker analysis (rs586123 G,
rs614197 G and rs2055729 C;Table 2).TheSNPs comprising these
three haplotypes displayed weak linkage disequilibrium (LD) with
the exception of the second and third SNP in the 59 haplotype
(r
2=0.55; Figure 2). Thus, the haplotypes are likely detecting
additional genetic variation that cannot be assessed by the tagging
SNPs on this array platform.
To evaluate whether the MSRA alleles identified here by
association could explain the former linkage signal on chromo-
some 8, the frequency of the T-G-A haplotype that showed the
strongest association signal was calculated in siblings with CF that
were concordant for MI. Sixteen sib-pairs contributed positively to
the LOD score while the remaining 14 sib-pairs had a negative
LOD score. The frequency of the T-G-A MSRA haplotype was
lower in siblings that contributed to linkage (5 of 64 chromosomes,
7.8%) compared to siblings that did not (12 of 44 chromosomes,
21.4%; P=0.033). Given that the T-G-A haplotype is associated
with a decreased rate of MI, it appears that the observed linkage with
risk for MI in our previous study was due to the increased sharing
of other MSRA haplotypes that confer a higher risk of MI.
A replication study was performed using CF patients recruited
by the CGS. The CGS is representative of the general CF
population in Canada and comprises approximately 70% of all
Figure 1. Regional association of SNPs within a region of linkage to MI on chromosome 8p23.1. The inset plot shows the locus linked to
MI on chromosome 8 identified by Blackman, et al [12]. The green shaded region under the peak extending from 17.9 cM (8.2 Mb) to 29.0 cM
(17.2 Mb), where LOD score .1, indicates the region analyzed in the main plot. The map position of MSRA is denoted by an arrow at ,20.2 cM. In the
main plot, P values are plotted in log scale versus physical location in Mb. The SNP showing the strongest association with MI, rs614197, is
represented by a diamond (P=8.35610
26). SNPs surrounding rs614197 are color coded to reflect their LD with this SNP (pair-wise r
2 using 1000
Genomes CEU, August 2009). The dashed line indicates the threshold for region-wide significance after Bonferroni correction for 2,896 SNPs
(P,1.73610
25). Genes, exon positions, and direction of transcription are denoted below plot (human genome build 18). Nine genes outside this
interval were omitted for display purposes: C8orf12, FAM167A, DEFB136, DEFB135, DEFB134, FAM66D, LOC392196, USP17L2, and FAM86B1. The blue
shaded region represents the 2 Mb encompassing rs614197 in which haplotype association was tested (see Figure S1).
doi:10.1371/journal.pgen.1002580.g001
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was 15.9% (n=220 with MI, 1,163 without MI), which is con-
sistent with the incidence of MI reported in numerous Caucasian
CF populations [8,10,16]. The frequency of the T-G-A haplotype
in the 1,335 CGS subjects in whom haplotypes were ascertained
was similar (15.4%) to that observed in the TSS (14.9%; Table 2).
Figure 2. Haplotype association in MSRA region. In this schematic, haplotypes comprised of three consecutive SNPs are represented as dots
connected by a line. Two overlapping haplotypes localized within intron 3 of MSRA had a statistically significant protective effect on MI
(P,1.73610
25 after Bonferroni correction for 2,890 haplotypes tested in a 2 Mb region): rs10903323 T – rs4840475 G – rs17151637 A and rs4840475
G – rs17151637 A – rs6601427 C. A ‘‘risk’’ haplotype upstream of MSRA, rs586123 G – rs614197 G – rs2055729 C, was just below the threshold for
significant association. Linkage disequilibrium patterns (pairwise r
2) are displayed below the rs numbers corresponding to each SNP (physical location
provided in Table 2).
doi:10.1371/journal.pgen.1002580.g002
Table 2. Key haplotypes in MSRA region showing association with MI in TSS cohort.
SNP 1 SNP 2 SNP 3 Haplotype
b Frequency P value
rs10903323 (10186977)
a rs4840475 (10190009) rs17151637 (10190492)
T G A T-G-A 0.149 1.08610
26*
T G G T-G-G 0.428 3.10610
23
T A A T-A-A 0.101 3.23610
21
T A G T-A-G 0.189 6.71610
21
C G G C-G-G 0.124 7.34610
21
rs4840475 (10190009) rs17151637 (10190492) rs6601427 (10193435)
G A C G-A-C 0.144 1.17610
25*
G G C G-G-C 0.290 6.48610
22
G G T G-G-T 0.264 1.47610
21
A A C A-A-C 0.095 2.21610
21
A G T A-G-T 0.177 9.08610
21
rs586123 (9823904) rs614197 (9825992) rs2055729 (9830072)
G G C G-G-C 0.186 1.99610
25{
G A T G-A-T 0.629 7.07610
24
G A C G-A-C 0.039 9.69610
22
A A C A-A-C 0.099 3.17610
21
G G T G-G-T 0.022 6.70610
21
aNumbers in parentheses indicate physical position on chr8 in base pairs (NCBI Build 36).
bAll observed haplotypes with frequency .1% are shown; bold indicates haplotypes noted in text.
*Protective haplotypes that reached statistical significance after Bonferroni correction for all 2,890 haplotypes tested (P,1.73610
25).
{Near significant risk haplotype containing rs614197 (italicized), the SNP that was most highly associated with MI in the initial analysis.
doi:10.1371/journal.pgen.1002580.t002
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sample under an additive model (OR=0.72, 95% CI [0.53–0.98],
P=0.04), in agreement with the initial finding in the TSS. The
incidence of MI in subjects with 0 copies of the T-G-A haplotype
was 17.3% (165/954 subjects), 13.1% (46/351) in those with 1
copy and 10% (3/30) in those with 2 copies.
The concept that variation in CFTR influences the risk of MI is
evident from the observation that a PI state (primarily determined
by CFTR genotype) is required for the development of MI [14].
However, there is a finer correlation between CFTR genotype and
MI as two CFTR mutations that are highly correlated with PI,
p.Gly551Asp and p.Gly542X, have been shown to decrease or
increase MI risk, respectively, from that conferred by the common
mutation p.Phe508del [14–16]. As p.Gly551Asp is present at a
relatively high frequency among European CF alleles (,2% [41]),
we evaluated the association between this mutation and MI in the
TSS and CGS cohorts. The incidence of MI in p.Gly551Asp-
bearing subjects was 7.8% in the TSS (n=51) and 5.9% in the
CGS (n=51), compared to 20.5% (n=507) and 17.9% (n=851)
in p.Phe508del homozygotes (P=0.026, 0.033), respectively.
Combining these two samples of CF subjects demonstrated that
the odds of MI in subjects with p.Gly551Asp was about a third of
that in p.Phe508del homozygotes (OR=0.32, 95% CI [0.13–
0.76]; P=0.010), comparable to the report by Hamosh, et al [15].
The finding that variation in the disease-causing gene alters the
incidence of MI even among PI subjects suggested that the
relationship between MI and the MSRA haplotype could be
confounded by variation in CFTR. To control for genetic
heterogeneity in CFTR, we tested for association between the T-
G-A haplotype and MI by evaluating 1,017 subjects with the same
genotype (p.Phe508del homozygotes) drawn from the TSS MI
families (n=166) and CGS studies (n=851). A meta-analysis
conducted using logistic regression coefficients and standard errors
[42] from individual TSS and CGS analyses revealed that the T-
G-A haplotype retained an additive protective effect (P=0.001),
indicating that MSRA modifies MI independently of variation in
CFTR.
Msra modifies intestinal obstruction and survival in CF
mice
Intestinal obstruction at the time of weaning is the primary cause of
death in mouse models of CF [22,43]. As the effect of the MI-
associated haplotypes upon MSRA expression was unknown, we
elected to introduce null alleles of Msra into mouse models of CF with
high and low rates of mortality due to intestinal obstruction to detect
whether loss of Msra expression reduced or exacerbated the rate of
obstruction. Intestinal obstruction in a null CF mouse model (C57BL/
6J Cftr
2/2) leads to high mortality (.80% [17]) by 40 days of age while
lower rates of mortality [44] occur in a CF mouse model (C57BL/
6J
R117H/R117H) with a targeted knock-in of a missense mutation
(p.Arg117His) associated with residual CFTR function [45,46] and
very low rates of MI in humans with CF [47]. Mice heterozygous for
the Cftr null (Cftr
+/2) or p.Arg117His allele (Cftr
+/R117H)w e r ec r o s s e dt o
mice with one or two Msra null alleles to produce CF mice (Cftr
2/2 or
Cftr
R117H/R117H)w i t hw i l d - t y p e( +/+), heterozygous (+/2), and null
(2/2) Msra genotypes. As expected, Cftr
2/2 mice displayed a sharp
drop in survival around the time of weaning when solid food is
introduced to the diet (Figure 3). The median survival of the Cftr
2/2
mice was 22 days, consistent with the high rates of mortality
due to intestinal obstruction reported in other CF ‘null’ mice
[17,18,24,48], all of which would have been homozygous for wild-
type Msra (i.e. Msra
+/+). However, survival was significantly
improved in Msra
+/2 and Msra
2/2 CF mice compared to their
Msra
+/+ littermates (P=0.022 and P=1.2610
24, respectively, by
log-rank test; Figure 3A). At the end of the follow-up period, 61% of
Msra
2/2 and 42% of Msra
+/2 mice were still living compared to
17% of Msra
+/+ mice. The increasing trend in survival across
genotypes (Ptrend=1.3610
24) mirrors the additive effect of the
MSRA haplotype observed in humans. As anticipated, Cftr
R117H/
R117H mice displayed reduced mortality, notably through the
weaning period, compared to Cftr-null mice (64.3% of Msra
+/+ mice
alive at 40 days, n=14; Figure 3B). However, there was no
difference in the rate of survival between Msra
+/+ mice and mice
with one Msra null allele (Msra
+/2: 76.5% alive at 40 days, n=51;
P=0.33, log-rank test) or two null alleles (Msra
2/2: 70.6% alive at
40 days, n=51; P=0.51). Mortality due to intestinal obstruction
Figure 3. Kaplan-Meier survival curves in CF mice according to
Msra genotype. A. CF mice homozygous for a null Cftr allele (Cftr
2/2)
and wild-type for Msra show high mortality due to intestinal
obstruction around the time of weaning (ca. 21 days; n=30). In
contrast, survival is markedly improved in Cftr
2/2 mice lacking one
(n=33) or two Msra alleles (n=46) compared to wild-type (P=0.022
and P=0.0001, respectively; log-rank test). B. CF mice homozygous for a
missense Cftr allele (Cftr
R117H/R117H) and wild-type for Msra display a low
rate of mortality due to intestinal obstruction around the time of
weaning (n=14). Survival is not affected in Cftr
R117H/R117H mice lacking
one (n=51) or two (n=51) Msra alleles compared to wild-type.
doi:10.1371/journal.pgen.1002580.g003
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intact, and these were primarily animals that succumbed after
weaning. Thus, loss of Msra expression increased survival in Cftr
2/2
mice by reducing the rate of fatal intestinal obstruction.
Excessive mucus accumulation in the crypts and lumen along
with goblet cell hyperplasia are characteristic findings in the small
and large intestine of Cftr
2/2 mice [17,22,43]. As goblet cells are
the primary source for mucus in the intestine, we sought to
determine if the goblet cell content of villi observed in the ileum of
15 day old mice is affected by Msra expression (Figure 4A). In wild-
type (WT; i.e. non-CF) mice, goblet cell counts per villus ranged
from 7.6% to 19.7% with a median of 11.1% (Figure 4B). The
fraction of goblet cells in Msra
2/2 mice was similar to WT,
ranging from 5.8% to 19.9% with a median of 13.0%, while the
fraction of goblet cells in Cftr
2/2 mice had a wider range, 12.4%
to 90.1%, and higher median (23.7%) than WT or Msra
2/2 mice
(Figure 4B). The fraction of goblet cells in WT and Msra
2/2 mice
and the increased proportion in Cftr
2/2 mice is comparable to the
numbers reported in other studies [29,31]. Like the Cftr
2/2 mice,
goblet cell fraction in the ileum of Cftr
2/2Msra
2/2 mice varied
widely, ranging from 16.3% to 90.1% with a median of 25.9%
(Figure 4B). Cftr
2/2 and Cftr
2/2Msra
2/2 mice displayed consid-
erable heterogeneity in the fraction of goblet cells per section with
both groups having a subset of villi where ,90% of cells were
goblet cells (two sections in Cftr
2/2 and four in Cftr
2/2Msra
2/2).
As goblet cell fractions were not normally distributed for the
Cftr
2/2 and Cftr
2/2Msra
2/2 mice, we evaluated these differences
using the non-parametric Mann-Whitney test. WT and Msra
2/2
mice had similar distributions (P=0.97) whereas both differed
significantly from Cftr
2/2 (WT: P=7.6610
25; Msra
2/2:
P=2.6610
24). Similarly, Cftr
2/2Msra
2/2 mice differed from
WT (P=2.4610
25) and Msra
2/2 mice (P=3.8610
25). However,
the distributions in Cftr
2/2 and Cftr
2/2Msra
2/2 did not differ
when all observations were included (P=0.67) or when the
sections with goblet cell fractions exceeding 89% were excluded
(median 22.2% vs. 22.3%, respectively; P=0.26). Thus, loss of
Msra expression does not appear to affect goblet cell hyperplasia in
the ileum of CF mice despite reducing intestinal obstruction and
increasing survival.
Discussion
Neonatal intestinal obstruction (also known as meconium ileus
or MI) has incomplete penetrance (15%) and high heritability
(,1.0) suggesting a prominent role for modifier genes in this
complication of CF [12]. Both candidate gene and genome-wide
studies indicate that multiple genetic modifiers of low effect
contribute to this trait in humans and in mice [12,19,49,50]. The
polygenic etiology of MI combined with its low incidence in CF
present a substantial challenge to identifying the responsible
genetic modifiers. However, by employing both linkage and
transmission methods in a family-based study followed by
replication in an unrelated sample of CF patients, we were able
to implicate the MSRA gene on chromosome 8. To test whether
manipulation of Msra expression modified intestinal obstruction in
the CF mouse, we elected to use a null allele of Msra to avoid
temporal or spatial issues that might have complicated a transgenic
over-expression strategy. As we did not know if loss of expression
would increase or decrease the rate of obstruction, we employed
two CF mouse models with different rates of mortality due to
intestinal obstruction at the time of weaning. Our hypothesis was
that the CF null model (with high rates of obstruction) would
reveal whether loss of Msra function decreased obstruction while the
p.Arg117His model (with lower rates of obstruction) would reveal
whether loss of Msra function increased obstruction. Indeed,
reduction of Msra expression in the null CF mouse model resulted
in a significant decrease in intestinal obstruction. The lack of effect
in the p.Arg117His CF mice suggested that the modifying effect of
Msra did not exceed the reduction in obstruction conferred by
residual function of CFTR bearing p.Arg117His. Together, the
two CF mouse models indicated that loss of Msra afforded
protection from intestinal obstruction during the time of weaning.
Figure 4. Histology of small intestine and goblet cell fraction of
villi in WT, Cftr
2/2, Msra
2/2, and Cftr
2/2Msra
2/2 mice. A. PAS/
Alcian blue stained sections of ileum from 15 day old mice. Genotypes
are shown in the bottom right hand corner of each section. Goblet cells
laden with acid mucin are stained blue. The Cftr
2/2 section
demonstrates mucus accumulation in the lumen and crypts with
blunted and necrotic villi. B. Percentage of goblet cells per villus
epithelial cells in the ileum of 15 day old mice. Each dot represents one
section. Median goblet cell densities (indicated by red lines) were 11.1%
in WT (n=4 mice; 10,919 cells counted in 18 sections), 13.0% in Msra
2/2
(n=3 mice; 9,586 cells counted in 17 sections), 23.7% in Cftr
2/2 (n=2
mice;4,762 cellscountedin11sections), and25.9% inCftr
2/2Msra
2/2mice
(n=3 mice; 6,396 cells counted in 12 sections).
doi:10.1371/journal.pgen.1002580.g004
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stem cells, and mortality from obstruction is nearly 100% in mice
on the 129 background [17]. Thus, it is unlikely that variation in
the 129-derived region surrounding Msra is responsible for the
reduced intestinal obstruction. Furthermore, the Msra region in
mice displays minimal synteny with the region surrounding MSRA
on chromosome 8 in humans. For example, tankyrase (TNKS), a
gene adjacent to the 59 end of MSRA in humans is not adjacent to
Msra on chromosome 14 in the mouse but is located on mouse
chromosome 8. The mouse studies provide compelling evidence
supporting the contention that MSRA modulates MI in humans.
Interestingly, non-CF Msra
+/2 mice have previously been shown
to have reduced lifespan thought to be the consequence of enhanced
vulnerability to oxidative stress compared to wild-type animals
[51]. In contrast, we observed longer survival in CF mice lacking
Msra. Our opposing finding suggests that in the disease context of
CF, having less Msra affords a protective benefit.
The initial starting point in our modifier gene search was a
9 Mb region on chromosome 8 within a region linked to risk for
MI in 30 concordant sibling pairs [12]. Association analysis of 133
families using transmission disequilibrium testing identified a single
SNP (rs614197) that achieved region-wide significance. Lack of
significant association between MI and this SNP in the CGS
sample motivated us to search for evidence of untyped alleles using
haplotype analysis. The association of both ‘protective’ and ‘risk’
haplotypes with MI led us to surmise that alleles of different effect
exist in or near MSRA. We then tested whether the ‘protective’
MSRA haplotype had a similar influence on MI in an independent
CF sample. While the TSS sample was potentially subject to
ascertainment bias due to its recruitment criteria (i.e. having a
sibling with CF), the CGS sample was ideal for replication as
recruitment was based only on a diagnosis of CF, and the sample
comprises 70% of the patients with CF in Canada. The significant
correlation between the ‘protective’ haplotype and reduced
incidence of MI in the CGS sample and conformity with an
additive model provided reassurance that variants in MSRA
modified MI risk. Finally, as several studies, including the present
study, have indicated that the CFTR genotype can affect the rate of
MI [14–16], we evaluated whether CFTR allelic variation
contributed to the association between the MSRA haplotype and
MI. The T-G-A haplotype associated with MI in an additive
fashion in individuals with identical CFTR genotypes (p.Phe508del
homozygotes), thereby demonstrating that MSRA modifies MI
independently of variation in CFTR, the disease-causing gene.
Heterogeneity of effect appears to explain the observed linkage of
risk for MI to the region encompassing MSRA. As noted above, the
T-G-A haplotype demonstrating robust association with MI
conferred protection from MI rather than risk for MI. However, this
is not the most common haplotype (,15%); thus most siblings carry
other haplotypes derived from the alleles of the three SNPs that, by
definition, confer higher risk for MI than the protective T-G-A
haplotype. As predicted by this assumption, the T-G-A haplotype
was significantly underrepresented in siblings concordant for MI
who contributedto thelinkagesignalonchromosome8.Bythe same
token, the T-G-A haplotype was over represented in siblings who did
not contribute to linkage. Hence, the observed modest linkage in
siblings concordant for MI was the result of sharing of neutral MSRA
haplotypes or haplotypes conferring risk for MI, and lack of sharing
of alleles associated with protection from MI. Sequencing of the
coding regions of MSRA in three CF subjects with MI and no T-G-A
haplotypes and in three subjects without MI and two T-G-A
haplotypes did not identify any plausible causative variants (data not
shown). Thus, we conclude that the haplotypes are tagging as yet
unidentified genetic variation within or near MSRA.
Central roles for luminal hydration and mucus production in
intestinal obstruction in CF mice at the time of weaning have been
supported by the manipulation of expression of two genes. In one
study, reduced expression of the sodium hydrogen exchanger
(Nhe3) led to decreased intestinal sodium absorption, thereby
increasing the hydration of luminal contents, alleviating obstruc-
tion, and improving survival [29]. Similarly, knock-out of the
mucin gene Muc1 in CF mice improved survival due to reduced
intestinal mucus content and less obstruction at the time of
weaning [30]. As noted by many others [22,43] as well as in this
study, goblet cell hyperplasia is a consistent histologic feature in
the small and large intestines of CF mice. However, the role of
goblet cells in intestinal obstruction in CF mice is not clear [43].
Reduced expression of Nhe3 relieved obstruction and eliminated
goblet cell hyperplasia [29] while increased expression of the
goblet cell marker Clca3 (Gob5) relieved obstruction and increased
goblet cell hyperplasia in CF mice [31]. Rozmahel and colleagues
suggested that Clca3 may reduce mucin release from goblet cells,
given the observation of increased goblet cell size, thereby
reducing luminal mucus content and intestinal obstruction in the
CF mice [31]. Evidence of association between MI and the
p.Ser357Asn variant in CLCA1, the human ortholog of the murine
Clca3, in 682 European CF subjects suggests that this goblet cell
marker may also contribute to intestinal obstruction in humans
[52]. Thus, alteration of mucus content in the CF intestine, either
by reduction in goblet cell numbers or down-regulation of mucus
release, appears to affect the rate of intestinal obstruction. Our
analysis indicated that loss of Msra expression did not affect goblet
cell hyperplasia in the Cftr
2/2 ileum despite mitigating intestinal
obstruction; thus the link between Msra and intestinal obstruction
in the context of CF is not immediately clear.
In humans, loss of CFTR function leads to a combination of
impaired pancreatic secretion of proteolytic enzymes and deficient
luminal hydration of meconium [53,54]. Consequently, meconium
from CF neonates is abnormally proteinaceous compared to that
of normal neonates, and it has been proposed that the altered
viscoelastic properties of meconium predispose fetuses and
neonates with CF to intestinal obstruction [55]. In young CF
mice, pancreatic exocrine function is relatively preserved [17].
However, inadequate hydration and excessive mucus secretion
leads to distension of the crypts of Lieberku ¨hn in the ileum and
colon and formation of concretions that appear to play a role in
obstruction [17,22,23,56]. MSRA encodes an antioxidant enzyme
that modifies the activity of certain proteins by reducing
methionine residues [57]. It is expressed in the intestine and other
tissues, particularly the liver, kidney, and brain [58–60]. A possible
link between MSRA and MI may be that MSRA can modulate the
activity of proteolytic enzymes [61]. Maximizing the activity of any
residual enzymes produced by the fetal pancreas would likely
contribute to the breakdown of intestinal proteins in utero, thereby
reducing the risk of obstruction. Evidence that MSRA modifies
intestinal obstruction provides new opportunities to investigate the
above concepts and the mechanisms underlying intestinal
obstruction in mice and in humans lacking CFTR.
Materials and Methods
Ethics statement
This study was approved by the institutional/ethical
review boards of all participating institutions. Written, informed
consent or assent was obtained from all subjects before enrollment
in the study. Experiments on mice were approved by the Case
Western Reserve University Institutional Animal Care and Use
Committee.
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Study subjects were derived from the North American CF
Modifier Gene Consortium, which is comprised of three
independent collections of CF subjects. Subjects in the discovery
sample were part of the Cystic Fibrosis Twin and Sibling Study
(TSS) at Johns Hopkins University (n=1,125 subjects). Enrollment
was based on conclusive diagnosis of CF [62]. Methods for
isolation of patient DNA [63] and identification of CFTR
mutations [64,65] have been previously described. The diagnosis
of MI was based on the presence of the following features in the
newborn period: lack of passage of stool within 24 hours after
birth, evidence of intestinal obstruction on abdominal radiograph
(ground-glass appearance of intestine, air-fluid levels, and/or
intra-abdominal calcifications), evidence of colonic abnormality
(microcolon on radiograph), and treatment for obstruction (enema
or surgery). Individuals with clinically defined PS, a CFTR
mutation associated with PS, or unknown pancreatic status were
excluded (n=143), as was one subject with unknown MI status.
The primary analysis was conducted in 133 ‘‘MI families’’ in
which at least one sibling was affected with MI (270 subjects, 169
parents). Case/control analyses were restricted to persons of self-
reported European descent to minimize the potential for spurious
associations due to race-related differences in allele frequencies;
whereas the primary family-based transmission analysis, which
was robust against population stratification, included an additional
23 individuals of non-European or mixed descent.
Findings from the primary analysis were tested in an independent
sample which has been described elsewhere [34]. The replication
population consisted of 1,573 CF subjects from the CGS [40]. All
subjects were defined as having PI. Exclusion of non-whites yielded
1,383 subjects (including 56 sib-ships) for analysis. Rates of MI in
subjects carrying the CFTR p.Gly551Asp mutation (c.1652G.A) or
who were homozygous for p.Phe508del were evaluated in the entire
TSS sample and the CGS sample. Subjects with p.Gly551Asp
carried this mutation in trans with another PI-associated mutation:
p.Cys343X (c.1029delC), c.1585-1G.A, p.Lys1177SerfsX15
(c.3528delC), c.489+1G.T, p.Glu585X (c.1753G.T), p.Phe508del,
p.Gly542X (c.1624G.T), p.Gly551Asp, p.Asn1303Lys (c.3909C
.G), p.Arg553X (c.1657C.T), p.Val520Phe (c.1558G.T), or
p.Trp1282X (c.3846G.A). Mutation legacy names can be found
in the Cystic Fibrosis Mutation Database (http://www.genet.
sickkids.on.ca).
Genotyping
Linkage disequilibrium between SNPs was assessed using
Haploview (http://www.broad.mit.edu/mpg/haploview) [66].
DNA extracted from either whole blood or transformed
lymphocyte cell lines was hybridized to the Illumina Infinium
610-Quad SNP array platform for whole genome genotyping at
the McGill University and Ge ´nome Que ´bec Innovation Centre.
Genotyping was performed and stringent quality control measures
were employed simultaneously in both cohorts, and the quality of
SNP calls was deemed to be very high (0.004% discordance
between replicate samples). SNPs were excluded from analysis in
all cohorts if the call rate was ,90%, if the minor allele frequency
was ,1%, or if the Mendelian error rate was .1%. For family-
based studies, any marker displaying non-Mendelian inheritance
was dropped from analysis for any family with the error. A detailed
description of additional quality control measures can be found in
Wright, et al [34].
Statistical analysis
For the primary study, family-based association testing of SNPs
and haplotypes was performed using the PBAT module [67]
implemented within the Golden Helix HelixTree software package
(Golden Helix, Inc. Bozeman, MT, USA; http://www.goldenhelix.
com). A sliding-window approach was employed to test the
transmission of haplotypes composed of three adjacent SNPs
(frequency .1%). A 2 Mb region was selected for haplotype testing
as the number of possible unique haplotypes would be nearly equal
to the number of SNPs tested in the initial analysis. Therefore, to be
considered significant, a haplotype would have to reach the same
Bonferroni-corrected threshold (or higher) that was set for SNPs in
the initial analysis. An additive genetic model was applied under a
null hypothesis of linkage and no association, and standard
phenotypic residuals were used as offsets to increase the power of
the test statistic. Bonferroni correction was applied by multiplying
nominal P values by the total number of SNPs or haplotypes tested.
The SNP association plot was generated using LocusZoom 1.0
(http://csg.sph.umich.edu/locuszoom).
For case/control analyses, haplotypes were derived in the
primary and replication populations using an expectation-
maximization (EM) algorithm implemented in Golden Helix.
Statistical analysis was performed in Stata10 (StataCorp, College
Station, TX, USA). Comparison of MI status to the number of
copies of haplotypes was performed using Fisher’s exact test (using
only subjects with haplotypes that could be determined with 100%
posterior probability). Odds ratios comparing the odds of MI in
subjects with 0, 1 or 2 copies of the chr8 haplotype, thus assuming
an additive model, were estimated using logistic regression. For
subjects with more than one haplotype assignment, EM probabil-
ity estimates were used to weight haplotypes. For TSS subjects,
parental and sibling genotypes were utilized when possible to
resolve phase. For studies including siblings (TSS and CGS),
empiric standard errors account for the possibility of sib-pair
correlation [68].
Mouse studies
Mice heterozygous for a Cftr null allele, B6.129P2-Cftr
tm1Unc [17]
or for the Cftr missense allele p.Arg117His, B6.129S6-Cftr
tm2Uth [44],
and either homozygous or heterozygous for a null allele of Msra[51]
were generated as breeders to produce CF mice carrying the three
genotypes of Msra (+/+, +/2, and 2/2) used in this study. Mice
were housed at constant temperature (22uC) on a 12 hour light/
dark cycle. Cages were checked daily for births and for monitoring
health and survival of animals to 40 days. Mice were weaned at 21
days of age onto an enriched diet (9F Sterilizable Rodent Diet 7960,
Harlan Teklad, Madison, WI) and provided water ad libitum. Mice
were of mixed background, but predominantly C57BL/6J (.87%;
crossed a minimum of two generations to C57BL/6J and some
animals up to ten generations).
Genotyping was carried out on 7 to 10-day old animals and if
death occurred before this point, genotypes were determined from
carcasses. Cftr genotyping was performed as previously described
[44]. Msra genotyping was carried out using two primer sets to
generate a 579-bp product for the wild-type allele (forward 59-
GTGTGAGAATAAACAGATGTTCTATGC-39 and reverse 59-
GGGTTGAGTACACTCCTTTCA-39) or a 320-bp product for
the mutant null allele (forward 59-AAAGCGCCTCCCTACCCG-
39 and reverse 59-ACTGTGCCCAGTTTAGTCCGTG-39). Sam-
ples were amplified by an initial denaturation for 5 min at 95uC
followed by 35 cycles of 95uC for 30 sec, 59uC for 30 sec, and 72uC
for 30 sec. PCR products were fractionated on a 1% agarose gel.
Kaplan-Meier survival curves were plotted and differences in
survival were analyzed by the non-parametric test of trends and log-
rank test of equality using Stata10.
For histology, freshly harvested tissues were fixed in 10%
formalin. Tissue was embedded in paraffin, sectioned at 5 mm
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microscopy. Deparaffinized slides were stained with Alcian blue
and periodic acid Schiff (PAS) stains, then counterstained with
acidified Harris hematoxylin. Comparison of goblet cell propor-
tions between groups was performed using the non-parametric
Mann-Whitney test.
Supporting Information
Figure S1 Haplotype association in MSRA region. Three-SNP
haplotypes were tested for association within a 2 Mb window
flanking the most highly associated SNP from the initial analysis
(rs614197, bold). P values are plotted in log scale versus physical
location in Mb. Each dot represents the mean position of the three
consecutive SNPs comprising a given haplotype. Two overlapping
haplotypes were significantly associated with protection against MI
after Bonferroni correction for 2,890 observed haplotypes (dashed
line; P,1.73610
25) and a third haplotype just below this
threshold was associated with risk for MI. The two protective
haplotypes are localized within intron 3 of MSRA and the ‘‘risk’’
haplotype is 59 to MSRA, as shown in Figure 2. The SNPs
comprising these haplotypes (larger dots) are labeled and
underlining indicates SNPs in common between haplotypes.
Genes, exon positions, and direction of transcription are denoted
below plot.
(JPG)
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